Consonance-Hfw Acq Corp (SRZN)

$12.08 +0.23 (1.94%)
Market Cap 39.26M
Revenue (ttm) 0.00
Net Income (ttm) -43.04M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 32,300
Avg Vol 46,560
Day's Range N/A - N/A
Shares Out 3.25M
Stochastic %K 25%
Beta 0.77
Analysts Strong Sell
Price Target $45.00

Latest News on SRZN

Surrozen to Present at Upcoming Healthcare Investor Conferences

Nov 6, 2024, 4:30 PM EST - 2 months ago

Surrozen to Present at Upcoming Healthcare Investor Conferences

Surrozen Provides Third Quarter 2024 Financial Results and Business Update

Nov 6, 2024, 9:00 AM EST - 2 months ago

Surrozen Provides Third Quarter 2024 Financial Results and Business Update

Surrozen and TCGFB, Inc. Announce Strategic Research Collaboration to Develop TGF-β Antibodies for Idiopathic Pulmonary Fibrosis

Nov 4, 2024, 8:30 AM EST - 2 months ago

Surrozen and TCGFB, Inc. Announce Strategic Research Collaboration to Develop TGF-β Antibodies for Idiopathic Pulmonary Fibrosis

Surrozen Earns $10 Million Milestone Payment in Retinal Diseases Collaboration

Sep 24, 2024, 8:30 AM EDT - 4 months ago

Surrozen Earns $10 Million Milestone Payment in Retinal Diseases Collaboration

Surrozen Provides Second Quarter 2024 Financial Results and Business Update

Aug 12, 2024, 4:05 PM EDT - 5 months ago

Surrozen Provides Second Quarter 2024 Financial Results and Business Update

Surrozen Publishes Study in ‘eLife' Demonstrating the Promise of The Proprietary SWEETS Platform, a Unique Targeted Protein Degradation Technology, to Further Enhance Wnt Signaling

Jun 12, 2024, 8:30 AM EDT - 7 months ago

Surrozen Publishes Study in ‘eLife' Demonstrating the Promise of The Proprietary SWEETS Platform, a Unique Targeted Protein Degradation Technology, to Further Enhance Wnt Signaling

Surrozen Presents Preliminary Results from Phase 1a Study of SZN-043 in Healthy Volunteers and Patients with a History of Liver Cirrhosis at the 2024 European Association for the Study of the Liver (EASL) in Milan

Jun 10, 2024, 8:30 AM EDT - 7 months ago

Surrozen Presents Preliminary Results from Phase 1a Study of SZN-043 in Healthy Volunteers and Patients with a History of Liver Cirrhosis at the 2024 European Association for the Study of the Liver (EASL) in Milan

Surrozen Initiates Dosing of First Patient in Phase 1b Clinical Trial of SZN-043 for Severe Alcohol-Associated Hepatitis

Jun 4, 2024, 8:30 AM EDT - 8 months ago

Surrozen Initiates Dosing of First Patient in Phase 1b Clinical Trial of SZN-043 for Severe Alcohol-Associated Hepatitis

Surrozen Presents Data Demonstrating the Promise of Antibody-Based Wnt Mimetics in Treating Cornea Endothelial Dystrophies and Dry Eye Disease at the Associations for Research in Vision and Ophthalmology (ARVO) Annual Meeting

May 9, 2024, 8:30 AM EDT - 9 months ago

Surrozen Presents Data Demonstrating the Promise of Antibody-Based Wnt Mimetics in Treating Cornea Endothelial Dystrophies and Dry Eye Disease at the Associations for Research in Vision and Ophthalmology (ARVO) Annual Meeting

Surrozen Provides First Quarter 2024 Financial Results and Business Update

May 8, 2024, 4:05 PM EDT - 9 months ago

Surrozen Provides First Quarter 2024 Financial Results and Business Update

Surrozen Publishes Study in 'Respiratory Research' Demonstrating the Promise of a Wnt Mimetic Antibody in Treating Pulmonary Fibrosis

Apr 3, 2024, 8:40 AM EDT - 10 months ago

Surrozen Publishes Study in 'Respiratory Research' Demonstrating the Promise of a Wnt Mimetic Antibody in Treating Pulmonary Fibrosis

Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043

Apr 1, 2024, 8:30 AM EDT - 10 months ago

Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043

Surrozen Announces up to $192.5 Million Private Placement of Securities Priced At-the-Market Under Nasdaq Rules

Apr 1, 2024, 8:30 AM EDT - 10 months ago

Surrozen Announces up to $192.5 Million Private Placement of Securities Priced At-the-Market Under Nasdaq Rules

Surrozen Provides Corporate Update on Clinical Programs

Jan 18, 2024, 8:30 AM EST - 1 year ago

Surrozen Provides Corporate Update on Clinical Programs

Surrozen Provides Third Quarter 2023 Financial Results

Nov 8, 2023, 4:05 PM EST - 1 year ago

Surrozen Provides Third Quarter 2023 Financial Results

Surrozen Provides Second Quarter 2023 Financial Results

Aug 9, 2023, 4:05 PM EDT - 1 year ago

Surrozen Provides Second Quarter 2023 Financial Results

Surrozen Publishes Study in Nature Communications Demonstrating the Promise of a Fzd4 Wnt Antibody in Treating Ischemic Stroke

Jun 5, 2023, 8:30 AM EDT - 1 year ago

Surrozen Publishes Study in Nature Communications Demonstrating the Promise of a Fzd4 Wnt Antibody in Treating Ischemic Stroke

Surrozen Provides First Quarter 2023 Financial Results and Corporate and Pipeline Updates

May 10, 2023, 4:05 PM EDT - 1 year ago

Surrozen Provides First Quarter 2023 Financial Results and Corporate and Pipeline Updates

Surrozen Strengthens Board of Directors with the Appointment of Eric Bjerkholt

Apr 5, 2023, 8:30 AM EDT - 1 year ago

Surrozen Strengthens Board of Directors with the Appointment of Eric Bjerkholt

Surrozen, Inc. (SRZN) Q4 2022 Earnings Call Transcript

Mar 25, 2023, 10:02 AM EDT - 1 year ago

Surrozen, Inc. (SRZN) Q4 2022 Earnings Call Transcript

Surrozen Provides Fourth Quarter and Full Year 2022 Financial Results and Update on Clinical Pipeline and Corporate Progress

Mar 22, 2023, 4:01 PM EDT - 1 year ago

Surrozen Provides Fourth Quarter and Full Year 2022 Financial Results and Update on Clinical Pipeline and Corporate Progress

Surrozen To Report Fourth Quarter and Full Year 2022 Financial Results and Provide a Corporate Update on March 22, 2023

Mar 20, 2023, 4:30 PM EDT - 1 year ago

Surrozen To Report Fourth Quarter and Full Year 2022 Financial Results and Provide a Corporate Update on March 22, 2023

Surrozen to Present at the 41st Annual J.P. Morgan Healthcare Conference

Jan 4, 2023, 4:41 PM EST - 2 years ago

Surrozen to Present at the 41st Annual J.P. Morgan Healthcare Conference

Surrozen Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Nov 14, 2022, 4:30 PM EST - 2 years ago

Surrozen Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Surrozen Presents Data on Two Lead Therapeutic Candidates at United European Gastroenterology (UEG) Week

Oct 10, 2022, 8:00 AM EDT - 2 years ago

Surrozen Presents Data on Two Lead Therapeutic Candidates at United European Gastroenterology (UEG) Week

Surrozen Announces Strategic Partnership with Boehringer Ingelheim to Develop Wnt Agonist SZN-413 for People with Retinal Diseases

Oct 6, 2022, 8:00 AM EDT - 2 years ago

Surrozen Announces Strategic Partnership with Boehringer Ingelheim to Develop Wnt Agonist SZN-413 for People with Retinal Diseases

Surrozen Publishes Study in Translational Vision Science and Technology Demonstrating the Promise of SZN-413 in Preclinical Models of Diabetic Retinopathy

Sep 26, 2022, 8:00 AM EDT - 2 years ago

Surrozen Publishes Study in Translational Vision Science and Technology Demonstrating the Promise of SZN-413 in Preclinical Models of Diabetic Retinopathy

Surrozen Reports Second Quarter 2022 Financial Results

Aug 11, 2022, 8:00 AM EDT - 2 years ago

Surrozen Reports Second Quarter 2022 Financial Results

Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-043 for Severe Alcoholic Hepatitis

Jun 13, 2022, 8:00 AM EDT - 2 years ago

Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-043 for Severe Alcoholic Hepatitis

Surrozen Presents Data on Lead Therapeutic Candidates at Digestive Disease Week (DDW)

May 24, 2022, 8:00 AM EDT - 2 years ago

Surrozen Presents Data on Lead Therapeutic Candidates at Digestive Disease Week (DDW)

Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-1326 for Moderate to Severe Ulcerative Colitis

May 18, 2022, 8:00 AM EDT - 2 years ago

Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-1326 for Moderate to Severe Ulcerative Colitis

Surrozen Publishes Article in Cellular and Molecular Gastroenterology and Hepatology Demonstrating that SZN-1326, a Selective Wnt Mimetic, Stimulated Robust Colon Epithelial Regeneration and Ameliorated Colitis in an Acute Model of Inflammatory Bowel Dise

May 16, 2022, 8:00 AM EDT - 2 years ago

Surrozen Publishes Article in Cellular and Molecular Gastroenterology and Hepatology Demonstrating that SZN-1326, a Selective Wnt Mimetic, Stimulated Robust Colon Epithelial Regeneration and Ameliorated Colitis in an Acute Model of Inflammatory Bowel Dise

Surrozen Reports First Quarter 2022 Financial Results

May 11, 2022, 8:00 AM EDT - 2 years ago

Surrozen Reports First Quarter 2022 Financial Results

Surrozen to Present at the BofA Securities 2022 Healthcare Conference

May 5, 2022, 8:00 AM EDT - 2 years ago

Surrozen to Present at the BofA Securities 2022 Healthcare Conference

Surrozen Presents Data Supporting Potential of SZN-413 for the Treatment of Diabetic Retinopathy at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

May 2, 2022, 8:00 AM EDT - 2 years ago

Surrozen Presents Data Supporting Potential of SZN-413 for the Treatment of Diabetic Retinopathy at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

Surrozen Reports Fourth Quarter and Full Year 2021 Financial Results

Mar 24, 2022, 8:00 AM EDT - 3 years ago

Surrozen Reports Fourth Quarter and Full Year 2021 Financial Results

Surrozen Announces Key 2022 Milestones for Lead Programs and Acceleration of Research Pipeline

Jan 10, 2022, 8:00 AM EST - 3 years ago

Surrozen Announces Key 2022 Milestones for Lead Programs and Acceleration of Research Pipeline

Surrozen to Present Virtually at the 40th Annual J.P. Morgan Healthcare Conference

Jan 5, 2022, 8:00 AM EST - 3 years ago

Surrozen to Present Virtually at the 40th Annual J.P. Morgan Healthcare Conference

Surrozen Reports Third Quarter 2021 Financial Results

Nov 15, 2021, 4:00 PM EST - 3 years ago

Surrozen Reports Third Quarter 2021 Financial Results

Surrozen to Present at The Piper Sandler 33rd Annual Healthcare Conference

Nov 15, 2021, 8:00 AM EST - 3 years ago

Surrozen to Present at The Piper Sandler 33rd Annual Healthcare Conference

Surrozen Presents Data Supporting Potential of SZN-043 at The Liver Meeting 2021, the Annual Meeting of the American Association for the Study of Liver Diseases

Nov 15, 2021, 8:00 AM EST - 3 years ago

Surrozen Presents Data Supporting Potential of SZN-043 at The Liver Meeting 2021, the Annual Meeting of the American Association for the Study of Liver Diseases

Surrozen to Present at The Stifel 2021 Virtual Healthcare Conference

Nov 5, 2021, 8:00 AM EDT - 3 years ago

Surrozen to Present at The Stifel 2021 Virtual Healthcare Conference

Surrozen's Inflammatory Bowel Disease Candidate Shows Encouraging Preclinical Action

Oct 6, 2021, 7:17 AM EDT - 3 years ago

Surrozen's Inflammatory Bowel Disease Candidate Shows Encouraging Preclinical Action

Surrozen Presented Data Supporting Potential of SZN-1326 at the 2021 United European Gastroenterology Week

Oct 5, 2021, 4:30 PM EDT - 3 years ago

Surrozen Presented Data Supporting Potential of SZN-1326 at the 2021 United European Gastroenterology Week

Surrozen Announces Appointment of Liz Nguyen as Vice President and Head of Human Resources

Sep 23, 2021, 8:30 AM EDT - 3 years ago

Surrozen Announces Appointment of Liz Nguyen as Vice President and Head of Human Resources

Here's why Surrozen shares are up more than 50% on Tuesday

Sep 7, 2021, 2:05 PM EDT - 3 years ago

Here's why Surrozen shares are up more than 50% on Tuesday

See Why Surrozen Stock Is Surging On Tuesday

Sep 7, 2021, 1:30 PM EDT - 3 years ago

See Why Surrozen Stock Is Surging On Tuesday

Surrozen Debuts as Publicly Traded Leader in Wnt Biology and Tissue Regeneration

Aug 11, 2021, 5:30 PM EDT - 3 years ago

Surrozen Debuts as Publicly Traded Leader in Wnt Biology and Tissue Regeneration

Surrozen to Present at Canaccord Genuity's 41st Annual Growth Conference

Aug 5, 2021, 8:00 AM EDT - 3 years ago

Surrozen to Present at Canaccord Genuity's 41st Annual Growth Conference

New Surrozen to Trade on Nasdaq as “SRZN”

Jul 30, 2021, 8:00 AM EDT - 3 years ago

New Surrozen to Trade on Nasdaq as “SRZN”